Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor & Stroma-Targeted Development.
The Urokinase Plasminogen Activator Receptor (uPAR, CD87, gene: PLAUR) is a GPI-anchored three-domain (D1-D2-D3) receptor central to the plasminogen activation system, driving tumor invasion, metastasis, and inflammatory tissue remodeling. Due to its restricted expression in normal tissues and overexpression in aggressive solid tumors (pancreatic, breast, glioblastoma) and tumor stroma, uPAR is a clinically validated oncology target with increasing momentum in ADC, radiopharmaceutical, CAR-T, and bispecific modalities. TarMart provides a validated toolkit—recombinant ECD proteins, lentiviral expression systems, pathway-specific antibodies, and ortholog panels—to support next-generation uPAR-targeted therapeutics.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for uPAR drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | uPAR / CD87 ECD-Fc Fusion (D1-D2-D3 Domains) High purity (>95%), endotoxin <1 EU/µg. Sequence verified. HEK293 expressed for native conformation and glycosylation. |
View uPAR Products |
| Gene Delivery | PLAUR Lentivirus Particles Full-length GPI-anchored ORF for stable cell line generation. Preserves native membrane topology, essential for flow cytometry and internalization assays. |
View uPAR Products |
| Benchmark Ab | Anti-uPAR (Sequence of Reference mAb) Recombinant positive control for assay calibration and binding confirmation. |
View uPAR Products |
| Validator | PLAUR siRNA Set For knockdown verification and specificity controls in functional assays. |
View uPAR Products |
| Ligand Control | uPA / PLAU Recombinant Protein Active urokinase for binding competition, co-crystal studies, and activation assays. |
View PLAU Products |
| Endocytosis Partner | LRP1 ECD Protein Scavenger receptor mediating uPAR internalization; critical for ADC trafficking and recycling studies. |
View LRP1 Products |
| Regulatory Target | PAI-1 / SERPINE1 Protein Primary uPA inhibitor; modulates uPAR activation status and signaling duration. |
View SERPINE1 Products |
| Co-receptor | Integrin Beta-1 (ITGB1) / Integrin Alpha-V (ITGAV) Form functional signaling complexes with uPAR, essential for cell migration and invasion assays. |
View ITGB1 Products / View ITGAV Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Evaluation (Human/Mouse/Cyno) | Ortholog panel available: Human, Mouse (Plaur), Cynomolgus uPAR proteins with >95% purity; sequence identity mapped for epitope conservation analysis. |
| Soluble uPAR (suPAR) Interference | Strictly quality-controlled ECD truncations (D1, D2-D3, full-length) for suPAR competition and PK assay development; domain-specific constructs for mechanistic shedding studies. |
| GPI-Anchor Membrane Topology & Stable Cell Lines | Premade lentivirus for robust, stable HEK293/CHO cell line generation (flow cytometry ready); ensures native lipid raft localization and avidity effects. |
| Specificity & Off-target Safety (Ly6 Family) | High-specificity protein standards with low endotoxin (<0.1 EU/µg option); sequence-confirmed absence of Ly6/PSCA cross-reactive motifs. |
| Internalization & Trafficking Assays (ADC Development) | Fluorophore-labeled uPA and anti-uPAR benchmark antibodies; compatible with Incucyte® and flow-based internalization quantification; pH-sensitive reagents available. |
Live uPAR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (uPAR/PLAUR)
- ➤ Latest Resistance & Metastasis Research
- ➤ Recent Patent Filings (uPAR Antibody & Biologics)
Global Clinical Landscape & Future Outlook
The race for uPAR (CD87) therapeutics is intensifying, with major players shifting from traditional enzyme inhibitors to targeted biologics that exploit the receptor's restricted tumor-associated expression. Because uPAR is a GPI-anchored receptor overexpressed in aggressive solid tumors (pancreatic, breast, glioblastoma) and tumor stroma (tumor-associated macrophages, cancer-associated fibroblasts), it offers a unique dual-targeting mechanism for both tumor cells and the microenvironment. First-generation ADCs and immunotoxins have reached Phase I/II trials for pancreatic, breast, and colorectal cancers. The next wave of R&D is focusing on highly internalized ADC payloads, next-generation radiopharmaceuticals for theranostics (e.g., 64Cu-DOTA-AE105 PET imaging), and uPAR-targeted CAR-T cells for refractory solid tumors. Overcoming the challenge of physiological soluble uPAR (suPAR) sink effect and LRP1-mediated recycling will be critical for clinical success.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Bicycle Therapeutics, Innovent Biologics, Fida Biotechnology | Pancreatic, Gastric, Breast, Colorectal | Internalization assay (need pH-sensitive probes + stable uPAR+ cell lines) |
| Radiopharmaceuticals / Imaging | Curium, Novartis, University Hospitals (Copenhagen, MGH) | Prostate Cancer, Glioblastoma, Pancreatic, Diagnostic PET | High-affinity screening (need ortholog proteins, low-endotoxin ECD for tracer validation) |
| CAR-T | CARsgen, Massachusetts General Hospital | Refractory Solid Tumors | Cytotoxicity assays (need lentivirus for target-overexpressing cell lines) |
| Bispecific (uPAR/CD3) | Emerging academic/industry consortia | Solid Tumors (T-cell redirection) | Cell-based killing assays (need stable uPAR+ lines with endogenous expression levels) |
| Immunotoxin | Next-gen constructs (deimmunized Pseudomonas exotoxin) | Bladder, Prostate Cancers | Binding affinity ranking (need species-cross reactive ECD proteins) |
| Small Molecule (Allosteric) | Preclinical biotechs | Fibrosis, Inflammation | uPA-uPAR binding inhibition (need purified components for PPI assay) |
Technical Note: uPAR is a GPI-anchored protein lacking a transmembrane domain. Traditional SPR assays using isolated ECD may miss avidity effects present in membrane-anchored formats. TarMart recommends parallel screening using both purified View uPAR Products ECD proteins and View uPAR Products Lentivirus-stable cell lines to capture full pharmacological profiles. The PLAUR gene harbors known single nucleotide polymorphisms (e.g., rs4251813, rs399145, rs4251878) that may affect antibody binding and should be considered during lead optimization.
Molecular Differentiation & Assay Strategy
Successful uPAR drug development requires addressing key differentiation criteria:
- Domain-Specific Epitope Selection: Targeting D1 directly blocks uPA binding (anti-metastasis) but is prone to shedding; targeting D2-D3 retains uPA binding but blocks integrin/LRP1 interactions. Use TarMart's D1-only, D2-D3-only, and full-length ECD constructs for epitope binning.
- Affinity & suPAR Competition: Leads must exhibit sub-nanomolar affinity to overcome soluble uPAR in serum. Perform SPR/BLI at pH 7.4 and pH 6.0 to emulate endosomal conditions.
- Cross-species Reactivity: Ensure binding to cynomolgus uPAR ( ~95% homology) for toxicology; avoid cross-reactivity with Ly6 family members (PSCA, CD59).
- Internalization Efficiency: Use stable cell lines (generated by View uPAR Products Lentivirus) and pHrodo-labeled antibodies to quantify endocytosis kinetics. Co-localization with LRP1 confirms trafficking.
- Cleavage-Resistant Mutants: Prepare for resistance by screening against MMP-9 cleavage-site mutants (e.g., R84A/R85A) available via custom protein engineering.
TarMart's integrated solutions cover all these needs, enabling efficient progression from hit identification to IND-enabling studies.